Terri Parker, MD

Assistant Professor of Medicine (Hematology); Assistant Professor

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: Not Applicable

Patient Care Organizations

Hematology

Yale Cancer Center: Hematology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Internal Medicine AB of Internal Medicine (2008)

  • Hospice & Palliative Medicine AB of Internal Medicine (2010)

  • Hematology (Internal Medicine) AB of Internal Medicine (2012)

  • Medical Oncology AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Leukemia, not otherwise specified, Myeloid and Monocytic Leukemia A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Multiple Myeloma A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma.
Multiple Myeloma Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
Multiple Myeloma An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602
Leukemia, other, Phase I A Phase I Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Myeloid and Monocytic Leukemia An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects
Hodgkin's Lymphoma, Leukemia, other, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Hematopoietic, Phase I An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
Multiple Myeloma A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Patients With Multiple Myeloma (MM)
Multiple Myeloma Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Multiple Myeloma Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Edit this profile

Contact Info

Terri Parker, MD
Patient Care Location
Yale Cancer CenterSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 7

New Haven, CT 06511
View on map...
Mailing Address
PO Box 208028
New Haven, CT 06520-8021